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Abstract
Introduction
Live attenuated oral vaccines against rotavirus (RV) have been shown to be less efficacious
in children from developing countries. Reasons for this disparity are not fully understood.
We assessed the role of maternal factors including breast milk RV-specific IgA, transpla-
centally acquired infant serum RV-specific IgG and maternal HIV status in seroconversion
among Zambian infants routinely immunized with Rotarix™ (RV1).
Methods
420 mother-child pairs were recruited at infant age 6–12 weeks in Lusaka. Clinical informa-
tion and samples were collected at baseline and at one month following the second dose of
RV1. Determination of breast milk RV-specific IgA and serum RV-specific IgA and IgG was
done using standardized ELISA. Seroconversion was defined as a 4 fold rise in serum
IgA titre from baseline to one-month post RV1 dose 2, while seropositivity of IgA was
defined as serum titre 40 and antibody variables were modelled on log-base 2. Logistic
regression was used to identify predictors of the odds of seroconversion.
Results
Baseline infant seropositivity was 25.5% (91/357). The seroconversion frequency was
60.2% (130/216). Infants who were IgA seropositive at baseline were less likely to serocon-
vert compared to their seronegative counterparts (P = 0.04). There was no evidence of an
association between maternal HIV status and seroconversion (P = 0.25). Higher titres of
breast milk rotavirus-specific IgA were associated with a lower frequency of seroconverson
(Nonparametric test for trend Z = -2.84; P<0.01): a two-fold increase in breast milk RV-spe-
cific IgA titres was associated with a 22% lower odds of seroconversion (OR = 0.80; 95% CI
= 0.68–0.94; P = 0.01). There was seasonal variation in baseline breast milk rotavirus-spe-
cific IgA titres, with significantly higher GMTs during the cold dry months (P = 0.01).
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Conclusion
Low immunogenicity of RV1 vaccine could be explained in part by exposure to high anti-
body titres in breast milk and early exposure to wild-type rotavirus infections. Potential inter-
ference of anti-RV specific IgA in breast milk and pre-vaccination serum RV specific-IgA
and IgG titres with RV1 seroconversion and effectiveness requires further research.
Introduction
Rotavirus (RV) kills half a million children each year worldwide including approximately
230,000 children in sub-Saharan Africa, making it the most significant contributor to diar-
rhoea-related child deaths worldwide [1–3]. RV is a vaccine-preventable illness. The demon-
strated effectiveness of RV vaccines, however, is generally low and highly variable in
developing countries [4,5]. Vaccines are among the most cost effective tools available to pre-
vent infectious diseases, and international guidelines recommend widespread roll-out of RV
vaccine [6,7]. Rotarix™ (GlaxoSmithKline Biologicals, Rixensart, Belgium), a monovalent
(RV1) attenuated human oral vaccine based on the G1P[8] RV strain [8], was recently intro-
duced in the routine immunisation programme in Zambia. Its safety and efficacy have been
established in healthy infants across multiple continents, including Africa [9–12]. However,
the vaccine has been found less efficacious among children in low income settings as compared
with middle income and industrialized countries for reasons not yet completely understood
[13–15]. Indeed, in a recent multicentre trial of RV1 conducted in South Africa and Malawi,
the vaccine showed substantially better efficacy in South Africa (76.9% efficacy) than in Malawi
(49.4% efficacy) [16].
It has been proposed that high background rates of malnutrition; other enteric co-infec-
tions; chronic diseases such as HIV, TB and recurrent malaria; co-administration of RV vac-
cine with OPV; and interference from passively acquired maternal antibody may all play a role
in this reduced vaccine responsiveness [17–22]. Other reports have investigated the potential
inhibitory role of acquired and innate immunological components of breast milk, which have
provided suggestive in-vitro evidence [21,23]. Lastly, rotavirus natural infection and disease
has been known to be high during the cool dry seasons, and indeed some reports have docu-
mented marked seasonal variations in rotavirus mortality and vaccine efficacy in children fol-
lowing national introduction of vaccines [13, 16]. In Zambia, seasonal trends for rotavirus
infection have also been reported [24–26].
We set out to evaluate the possible contribution of maternal RV-specific immunity factors
on failed infant seroconversion following routine RV vaccination in a cohort of 420 Zambian
mother-infant pairs. Here we present findings exploring associations of maternal factors and
seasonality, on infant seroconversion to RV immunisation.
Materials and Methods
Study site and participants
The study was conducted at Kamwala clinic, a peri-urban primary care health facility in
Lusaka, which provides basic outpatient and maternal child health services. Kamwala has a
catchment population of over 10,000 with approximately 120 new infants presenting each
month. The majority of the attendees to this public facility are low-income residents of two
nearby sprawling shanty compounds.
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Study recruitment was done between April 2013 and March 2014. We recruited participants
as they presented to the facility for routine immunisation service. Mother-infant pairs were
approached during the initial visit with study information. Those interested were provided
detailed information. Consenting mothers were administered a simple comprehension text and
those meeting the minimum understanding provided individual written consent. Mothers
unable to read or write were provided information through an impartial witness who provided
a signed confirmation together with thumbprint of the participant as confirmed written con-
sent. The pair was eligible if: i) the mother was willing to participate voluntarily and able to
provide signed informed consent (with witness in the case of illiterate participant); ii) the infant
was eligible for RV1 vaccine immunization as per national policy (male or female infant, aged
6–12 weeks old); iii) the mother was willing to undergo study procedures, including question-
naires, HIV counselling and testing, CD4 testing, and provide breast milk at enrolment; iv) the
mother was willing to allow her infant to undergo study procedures, including full-course RV1
vaccination, phlebotomy at enrolment and 1 month post full RV1 vaccination, and presenta-
tion to clinic for collection of stool sample when infant had diarrhoea; and v) planned to
remain in the area and was willing to come for scheduled visits for the duration of the study.
The University of Zambia Biomedical Research Ethics Committee, University of North
Carolina at Chapel Hill Institutional Review Board and the Zambian Ministry of Health
approved the study. This study did not require review by the Centers for Disease Control and
Prevention institutional review board because only de-identified specimens were tested there.
The study was conducted in accordance with the principles of the Declaration of Helsinki
and in compliance with good clinical practice guidelines; ClinicalTrials.gov registration num-
ber NCT 01886833.
Clinic procedures
Enrolled mothers provided demographic and medical history information and provided
expressed breast milk samples. Their delivery record was reviewed for information about their
HIV status, and where it was not documented, they underwent HIV counselling, testing and
CD4 count measurements.
Enrolled infants received a physical examination and a baseline serum sample was taken for
rotvirus-specific IgA and IgG antibodies. The infant was then administered the full expanded
programme on immunisation (EPI) vaccine regimen, which included the oral RV1 and polio
vaccines, and parenteral pentavalent vaccines (containing diphtheria, tetanus, pertussis, hae-
mophilus influenza, and hepatitis B). They were given an appointment card highlighting the
next scheduled visit (one month post the second RV dose) and were escorted home by a
research assistant in order to record the physical location of their residence, as there are no
street addresses in the clinic catchment area. The mothers were asked to bring the child to the
clinic anytime in case of illness of any kind. Arrangements for collection of stool samples were
made, in the event the child developed diarrhoea.
Laboratory procedures
Rotavirus-specific IgA in breast milk samples, and serum rotavirus specific-IgA and IgG were
determined by an antibody capture ELISA assay as described in detail previously [27]. Briefly,
microplate wells were coated with rabbit hyperimmune serum to rhesus rotavirus (RRV) and
incubated with diluted RV1 strain or blotto (5% skim milk in phosphate-buffered saline
[PBS]). After washing, breast milk and serum samples (1:20–1:20,480) that were serially diluted
in diluent buffer (1% skim milk and 0.5% [v/v] of 10% polyoxyethylene ether W1 in PBS) were
added to the wells, followed by biotin-conjugated goat antihuman IgA antibodies (KPL,
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Gaithersburg, Maryland). After incubation and washing, extravidin (Sigma, St. Louis, Mis-
souri) was added to the wells and incubated, and then the reactions were developed with
3,30,5,50-tetramethylbenzidine (TMB; Sigma) and stopped with 1N hydrogen chloride. Optical
density (OD) was determined at 450 nm with an enzyme immunoassay reader (MRX Revela-
tion; Dynex Technologies, Chantilly, Virginia). IgA titres in breastmilk and serum were calcu-
lated as the reciprocal of the highest dilution that gave a mean OD greater than the cut-off
value (3 standard deviations above the mean OD of the negative control serum wells). RV-spe-
cific IgG in serum samples was tested and analysed in the same manner as IgA except that
0.5% normal rabbit serum was added to the biotin-conjugated goat antihuman IgG antibody
(KPL, Gaithersburg, Maryland) solution.
Statistical analysis
Children were defined as having seroconverted when at 1 month post immunization, the rota-
virus specific-IgA titre increased by four fold or greater compared with the titre recorded before
the first dose of RV1. IgA titer40 in serum was considered positive. IgA titer< 20 in serum
is assigned a value of 1 for the calculation of GMTs. Pearson Chi-squared test was used to
investigate the association of seroconversion and categorical factors (i.e. age, sex, season,
maternal HIV status, and infant seropositivity at baseline) For breast milk rotavirus specific-
IgA and infant serum rotavirus specific-IgG categorized as quartiles, Wilcoxon rank-sum test
for trend was used.
Multivariable logistic regression was used to identify predictors of the odds of seroconver-
sion. The antibody variables were transformed into log base 2 scales and modelled as a continu-
ous covariate so that the effect would be interpreted as a doubling of antibody response. Season
was considered a priori as an important confounder and was modelled as a categorical variable
defined as 1 for dry (i.e. May to October at time of first dose) and 0 otherwise. In the multivari-
able model, covariates were included if the unadjusted P value for association with odds of
seroconversion was 0.2 or less. Criteria for removing variables were set at P value< 0.2, and
change in coefficients of variables is not more than 10%. Likelihood ratio test was used to inves-
tigate whether or not the effect of breast milk anti-rotavirus IgA on odds of seroconversion var-
ies between seasons.
Geometric mean titres (GMT) and 95% confidence intervals of infant serum rotavirus spe-
cific-IgA post dose 2 and breast milk rotavirus specific-IgA were calculated for Wet and Dry
seasons. With two dry seasons and one wet season, GMT’s of breastmilk were compared by
season as well as infant serum IgA GMTs post vaccine dose 2 using a t-test. Wilcoxon rank-
sum test was used to compare the median rotavirus specific-IgA titers in pre dose 1 breastmilk
between non-seroconvertors and seroconvertors. Data were analysed using Stata 14 (StatCorp,
College Station, Texas, USA).
Results
Of a total of 1320 infants and mothers were screened, 420 mother-infant pairs were successfully
enrolled. The most common reason for declining to participate was unwillingness for the
infant’s mother to have the infant’s blood drawn as shown in Fig 1.
Overall, the seroconversion frequency of IgA in the infants was 60.2% (130/216), while base-
line seropositivity was 25.2% (90/357). Infants who were rotavirus specific-IgA seropositive at
baseline were less likely to seroconvert compared to their seronegative counterparts (P = 0.04).
There was no evidence of an association between maternal HIV status and seroconversion
(P = 0.25). High titres of rotavirus specific-IgA in breast milk were associated with a lower fre-
quency of seroconversion (Wilcoxon rank-sum test for trend z = -2.84; P<0.01) (Table 1).
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When we plotted the cumulative frequency profiles of breastmilk rotavirus specific-IgA
titres by infant IgA seroconversion (defined as four-fold increase in rotavirus-specific IgA titres
in post dose 2 sera when compared to the corresponding pre-immunization sera), we observed
a clear separation of the curves as shown in Fig 2. The median rotavirus specific-IgA titres in
pre dose 1 breastmilk were significantly higher among non-seroconvertors compared with ser-
oconvertors (P = 0.01). In a multivariable model with adjustment for seasonality, there was
strong evidence of a 22% reduction in the odds of seroconversion, due to a two-fold increase in
breast milk RV-specific IgA titres (Adjusted OR = 0.78; 95% CI = 0.66–0.92; P<0.01)
(Table 2). When we analysed RV IgG levels in a univariable analysis, the doubling of infant RV
IgG levels at baseline was associated with a 17% lower odds of seroconversion (Unadjusted
OR = 0.83; P = 0.08).
We performed further analysis to examine the relationship between seasonality and
immune response as a cause of rotavirus vaccine failure and found that dry cold seasons were
significantly associated with higher IgA titers in breastmilk of mothers (Table 3). These higher
IgA titers in breastmilk during the cold dry months (May to June) were negatively associated
with IgA seroconversion to RV1 vaccination in infants. We observed an inverse trend between
pre-dose 1 IgA seropositivity and seroconversion, but the associations were not significant.
Discussion
In recent times, interference from maternal antibodies in breast milk has received particular
attention as cause of rotavirus vaccine failure [21]. Several efforts have been made in rando-
mised controlled trials of transient breastfeeding withholding around the time of vaccine
administration. However, results from South Africa [27], Pakistan [28] and India [29] found
no benefit from withholding breastfeeding around the time of immunisation. Although these
studies did not find a benefit in RV vaccine immunogenicity with transient breastfeeding
Fig 1. Study Participants Flow chart.
doi:10.1371/journal.pone.0150100.g001
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withholding, our results indicate a need to seek other interventions that may diminish potential
breast milk interference of RV vaccine response.
There are key considerations that need to be made in light of these reports in order to justify
continued research in this field. First, it remains debatable whether the hours of withholding
breastfeeding implemented in these trials were sufficient to remove that potential interference.
Second, in the case of the Asian trials, lower overall seroconversion rates were generally
observed (16.6% in the withholding arm and 29.1% in the immediate breastfeeding arm in
Pakistan; and 26.1% and 26.6% respectively in India), while our rate was much higher at 60.2%,
similar to the 61% observed in South Africa [27]. Despite the fact that different assays with dif-
fering cut-offs for positivity were used in these trials, it does appear that breast milk effects
could be variable depending on the background context and may still be the explanation for
some of the unexplained results from various studies.
Table 1. Percentage of infants seroconverted* by infant andmaternal factors, in Lusaka.
Characteristics Number of Infants (% of total) Number (%) seroconversion 95% CI Pearson Chi-square; P-value
Age at first RV1 (Weeks) n = 406 n = 211 5.38; 0.07
6 <7 249(61.3) 90(65.2) [56.8, 72.8]
7 <8 115(28.3) 24(47.1) [33.7, 60.8]
8–12 42(10.3) 12(54.6) [33.6, 74]
Sex of infant n = 420 n = 216 0.03; 0.87
Female 221(52.6) 65 (59.6) [50.1, 68.5]
Male 199(47.4) 65 (60.7) [51.1, 69.6]
Season n = 393 n = 216 0.41; 0.52
Wet 86(21.9) 13 (54.2) [34.1, 72.9]
Dry 307(78.1) 117 (60.9) [53.8, 67.6]
Maternal HIV status n = 412 n = 211 1.34; 0.25
Negative 287(69.7) 88 (62.0) [53.7, 69.6]
Positive 125(30.3) 37 (53.6) [41.7, 65.1]
Baseline infant serum IgA
seropositivity
n = 357 n = 216 4.19; 0.04
Seronegative 267(74.8) 105 (64) [56.3, 71.1]
Seropositive1 90(25.2) 25 (48.1) [34.8, 61.7]
Breast-milk rotavirus specific-
IgA (Quartiles)
n = 383 n = 210 -2.84; 0.01 2
1 (1–80) 170(44.4) 65 (70.7) [60.5, 79.1]
2 (160) 84(21.9) 26 (54.2) [39.9, 67.8]
3 (320) 67(17.5) 19 (51.4) [35.4, 67.1]
4 (640–5120) 62(16.2) 15 (45.5) [29.3, 62.7]
Infant serum rotavirus specific-
IgG (Quartiles)
n = 365 n = 215 -1.88; 0.06 2
1 (160–2560) 118(32.3) 53 (68) [56.7, 77.4]
2 (5120) 91(24.9) 32 (61.5) [47.6, 73.8]
3 (10240) 154(42.2) 44 (52.4) [41.6, 62.9]
4 (20480) 2(0.6) 1 (100) -
Total 420 (100) 130 (60.2) [53.5, 66.5]
* seroconversion = post immunization rotavirus specific-IgA titre increased  four-fold compared with the titre recorded before the first dose of RV1
1 Seropositivity of IgA was defined as titer  1:40.
2 Wicoxon rank-sum test for trend
Significant differences are shown in bold.
doi:10.1371/journal.pone.0150100.t001
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Our observations demonstrate the need to reconsider breast milk RV IgA carefully as a fac-
tor that could explain differential vaccine effectiveness rates between low, middle, and high-
income settings. Whereas there was no evidence of an association between maternal HIV status
and seroconversion (62% versus 54% respectively), infant seroconversion appeared to decrease
with increasing levels of breast milk anti-RV IgA titers (71%, 54%, 51 and 46% respectively for
each quartile).
Our proposed association between maternal immunity and infant seroconversion is further
strengthened by our observations of seasonality trends. Our findings are consistent with exist-
ing epidemiological literature about RV transmission cycles: RV infections peak in the cool,
dry season (April to July) and demonstrate a second, but smaller peak in the hot, dry season
(October to November) [24–26, 28–31]. This study has shown consistent seasonal trends
through GMT IgA titer in breast milk, reflecting the epidemiologic pattern when mothers
Fig 2. Cumulative frequency profiles of RV-IgA titres in pre dose 1 breastmilk of 216 mother-infant pairs by infant IgA seroconversion post dose 2
of rotavirus vaccine. Seroconversion was defined as four-fold increase in rotavirus-specific IgA titres in post dose 2 sera when compared to the
corresponding pre-immunization sera.
doi:10.1371/journal.pone.0150100.g002
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would likely be getting infected. Further strengthening our argument, statistically significant
differences in GMT tires have been seen by season among seroconvertors and non-seroconver-
tors, suggesting a negative relationship between breastmilk IgA titre and the post-dose 2 infant
serum IgA titre across seasons. This observation requires further investigations into whether
infants immunized in high RV transmission seasons yield lower seroconversion IgA titers, and
the suggestion that there may be some interaction between seroconversion and season. It
remains to be investigated whether the risk of clinical disease from RV is higher in infants with
low vaccine induced IgA titres.
Maternally acquired IgG did show a trend to affect seroconversion upon interquartile base-
line titre comparisons consistent with other studies [22]; however, in our study this association
did not reach statistical significance (p = 0.06). Indeed IgG has been more strongly implicated
Table 2. Maternal and infant factors independently associated with odds of seroconversion (N = 210).
Factors Unadjusted OR (95% CI) Unadjusted P-value Adjusted OR (95%CI) Adjusted P-value
Age at first RV1(Weeks)
6 <7 ref 0.07
7 <8 0.47(0.25,0.91)
8–12 0.64(0.26,1.59)
Season
Wet ref 0.52 ref
Dry 1.32(0.56, 3.10) 2.37(0.91, 6.17) 0.08
Maternal HIV status
Negative ref 0.25
Positive 0.71(0.40, 1.27) -
Infant serum rotavirus specific-IgG 1
Values transformed to log2 0.83(0.68, 1.02) 0.08 -
Breastmilk rotavirus specific-IgA 1
Values transformed to log2 0.80(0.68, 0.94) 0.01 0.78(0.66, 0.92) <0.01
doi:10.1371/journal.pone.0150100.t002
Table 3. Rotavirus-specific IgA in Breastmilk and sera, and RV-IgA serconversion (SC), by seasons (N = 200).
Breastmilk Infant’s sera
Season n IgA pre dose 1 GMT
(95%CI)
IgA pre dose 1
positivity (%)
IgA pre dose 1 GMT
(95%CI)
IgA post dose 2 GMT
(95%CI)
IgA SC
(%)
Dry season 2013
(May 2013–Oct 2013)
104 158 (122–204) (a) 27% 5 (4–8) 64 (37–110) 55% (d)
Rainy season 2013–14
(Nov 2013–April 2014)
31 85 (51–141) (b) 13% 5(3–10) 112 (50–252) 71% (e)
Dry season 2014
(May 2014–Oct 2014)
65 178 (140–227) (c) 20% 6 (3–9) 63 (31–130) 49% (f)
P value p = 0.031 1 p = 0.146 3
p = 0.010 2 p = 0.051 4
IgA seroconversion = post immunization rotavirus specific-IgA titre increased  four-fold compared with the titre recorded before the first dose of RV1
Seropositivity of IgA was defined as titer  1:40.
1 t-test (a) vs (b),
2 t-test (b) vs (c),
3 X2-test (d) vs (e),
4 X2-test (e) vs (f).
doi:10.1371/journal.pone.0150100.t003
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in affecting seroconversion in other studies [22,32,33]. In univariate analysis, doubling infant
IgG levels appeared to be associated with a 17% reduction in the odds of seroconversion but
the effect diminished after accounting for other covariates. It is apparent that VP7 and
VP4-specific immunoglobulin G (IgG) play an important protective role in natural infection
and vaccine-mediated immunity, especially if their production is of sufficient magnitude for
them to be exuded onto the mucosal surface where infection occurs [34–40]. These previously
reported data support the theory that placental transfer of RV-specific IgG impacts vaccine
effectiveness. In fact, higher antibody titre and higher rates of seroconversion and protection
have been observed in older children without maternal antibody, in comparison to those of
younger infants [38,41], suggesting maternal serum antibodies, in addition to those found in
breast milk, attenuate response to vaccine [32,42,43].
Another important finding from our study is the relatively high rate of rate of pre vaccina-
tion IgA seropositives. At 25% baseline seropositivity, our findings suggest that a quarter of the
infants are already exposed to rotavirus natural infection very early in life and these were less
likely to serconvert after vaccination. With a borderline significance (P = 0.04), possibly
because of our relatively small sample size, it remains to be concluded whether early natural
exposure could also negatively influence vaccine seroconversion as previously observed in
South Africa and Nicaragua [22, 27, 43].
The complexity and lack of understanding of seroconversion to vaccines and its meaning in
terms of clinical protection still prevails at this point. Infant factors, including nutritional sta-
tus, have been linked to RV diarrhoea. The relationship between malnutrition and RV vaccine
efficacy remains a subject of interest for our on-going research. There are other suggestive
reports that efficacy of oral vaccines is lower in poor hygiene settings where malnutrition is
common [44, 45]. The actual effect of protein energy malnutrition and micronutrient defi-
ciency on RV vaccine safety and efficacy is however not well understood [45,46].
Based on our findings, we conclude that there is a clear trend in the seasonal peaks of breast
milk IgA and corresponding troughs in infant serum IgA response to RV vaccination. This
inverse relationship suggests potential interference of maternal breast milk antibodies on sero-
conversion. The extent to which the effect of these maternal antibodies can be overcome by
withholding breast milk for various periods of time around child immunisation remains to be
demonstrated. Based on a number of studies in recent years [27, 32–34], It has become clear
that transient withholding of breastfeeding does not appear to help. Given the logistic chal-
lenges of withholding and overwhelming benefits of breastfeeding, the scientific community
seems to have largely decided to drop this transient intervention strategy. Nonetheless, we
believe long-term breastfeeding has a damping effect on RV vaccines. Thus, there is need for
further research into other interventions, strategies or approaches to explain this phenomenon.
Lastly, it remains to be proved whether infants exposed to these high breast milk antibody titres
are necessarily at higher risk of clinical disease.
As many LMICs seek to attain millennium development goals, reduction of child mortality
through interventions that include “effective child vaccines” is an important strategy. Research
such as ours, seeking to understand and explain challenges of achieving rotavirus vaccine
impact is of great importance.
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